Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 27;21(12):47.
doi: 10.1007/s11882-021-01023-w.

Pharmacogenetics of Bronchodilator Response: Future Directions

Joanne E Sordillo  1 , Rachel S Kelly  2 , Sharon M Lutz  1 , Jessica Lasky-Su  2 , Ann Chen Wu  3
Affiliations
Review

Pharmacogenetics of Bronchodilator Response: Future Directions

Joanne E Sordillo et al. Curr Allergy Asthma Rep. .

Abstract

Purpose of review: Several genome-wide association studies (GWASs) of bronchodilator response (BDR) to albuterol have been published over the past decade. This review describes current knowledge gaps, including pharmacogenetic studies of albuterol response in minority populations, effect modification of pharmacogenetic associations by age, and relevance of BDR phenotype characterization to pharmacogenetic findings. New approaches, such as leveraging additional "omics" data to focus pharmacogenetic interrogation, as well as developing polygenic risk scores in asthma treatment responses, are also discussed.

Recent findings: Recent pharmacogenetic studies of albuterol response in minority populations have identified genetic polymorphisms in loci (DNAH5, NFKB1, PLCB1, ADAMTS3, COX18, and PRKG1), that are associated with BDR. Additional studies are needed to replicate these findings. Modification of the pharmacogenetic associations for SPATS2L and ASB3 polymorphisms by age has also been published. Evidence from metabolomic and epigenomic studies of BDR may point to new pharmacogenetic targets. Lastly, a polygenic risk score for response to albuterol has been developed but requires validation in additional cohorts. In order to expand our knowledge of pharmacogenetics of BDR, additional studies in minority populations are needed. Consideration of effect modification by age and leverage of other "omics" data beyond genomics may also help uncover novel pharmacogenetic loci for use in precision medicine for asthma treatment.

Keywords: Bronchodilator response; Effect modification by age; Pharmacogenetics; Polygenic risk score; β2-agonist.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Joanne Sordillo, Sharon Lutz, Jessica Lasky-Su, and Rachel Kelly declare that they have no conflict of interest. Ann Chen Wu reports grants from GlaxoSmithKline, outside the submitted work.

References

    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017. - PMC - PubMed
    1. Martinez FD, Vercelli D. Asthma Lancet. 2013;382(9901):1360–72. - PMC - PubMed
    1. Billington CK, Penn RB, Hall IP. β2 Agonists. Handb Exp Pharmacol. 2017;237:23–40. - PMC - PubMed

    1. Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. Optimal asthma control: time for a new target. Am J Respir Crit Care Med. 2020;201(12):1480–7.

      This review discusses the current limitations of pharmacological treatment of adult asthma, and proposes the development of practical methods to identify treatable traits contributing to respiratory symptoms in asthma.

    1. McGeachie MJ, Stahl EA, Himes BE, Pendergrass SA, Lima JJ, Irvin CG, et al. Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes. Pharmacogenet Genomics. 2013;23(6):324–8. - PMC - PubMed

Publication types